Pain in multiple sclerosis: Prevalence, mechanisms, types and treatment;El dolor en la esclerosis múltiple: Prevalencia, mecanismos, tipos y tratamiento

Revista de Neurologia

Volumn 50, Issue 2, 2010, Pages 101-108

  Bermejo, Pedro E ^a   Oreja Guevara, Celia ^a   Díez Tejedor, Exuperio ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Cannabinoids; Headache; L'hermitte's sign; Multiple sclerosis; Optic neuritis; Pain; Trigeminal neuralgia

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; BOTULINUM TOXIN A; CANNABIDIOL; DRONABINOL; OPIATE; TRIPTAN DERIVATIVE;

CLINICAL FEATURE; DAILY LIFE ACTIVITY; DEPRESSION; DISABILITY SEVERITY; DISEASE DURATION; FATIGUE; HEADACHE; HUMAN; LIMB DYSESTHESIA; LOW BACK PAIN; MULTIPLE SCLEROSIS; MUSCLE SPASM; OPTIC NEURITIS; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR; TRIGEMINUS NEURALGIA;

EID: 76749087611     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5002.2008613     Document Type: Review

References (62)

1. Poser CM, Brinar VV. The accuracy of prevalence rates of multiple sclerosis: a critical review. Neuroepidemiology 2007; 29: 150-5.
2. Svendsen KB, Jensen TS, Hansen HJ, Bach FW. Sensory function and quality of life in patients with multiple sclerosis and pain. Pain 2005; 114: 473-81.
3. Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol 1984; 41: 1270-2.
4. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis: a 5-year follow-up study. Ital J Neurol Sci 1995; 16: 629-32.
5. Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, et al. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain 1994; 58: 89-93.
6. Kalia LV, O'Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler 2005; 11: 322-7.
7. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 1991; 84: 197-200.
8. Svendsen KB, Jensen TS, Overvad K, Hansen HJ, Koch N, Bach FW. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol 2003; 60: 1089-94.
9. Hadjimichael O, Kerns RD, Rizzo MA, Cutter G, Vollmer T. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain 2007; 127: 35-41.
10. Ehde DM, Osborne TL, Hanley MA, Jensen MP, Kraft GH. The scope and nature of pain in persons with multiple sclerosis. Mult Scler 2006; 12: 629-38.
11. Osborne TL, Jensen MP, Ehde DM, Hanley MA, Kraft G. Psychosocial factors associated with pain intensity, pain-related interference, and psychological functioning in persons with multiple sclerosis and pain. Pain 2007; 127: 52-62.
12. Kerns RD, Kassirer M, Otis J. Pain in multiple sclerosis: a biopsychosocial perspective. J Rehabil Res Dev 2002; 39: 225-32.
13. O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 2008; 137: 96-111.
14. Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008; 22: 291-324.
15. Kenner M, Menon U, Elliott DG. Multiple sclerosis as a painful disease. Int Rev Neurobiol 2007; 79: 303-21.
16. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis -prevalence and clinical characteristics. Eur J Pain 2005; 9: 531-42.
17. Indaco A, Iachetta C, Nappi C, Socci L, Carrieri PB. Chronic and acute pain syndromes in patients with multiple sclerosis. Acta Neurol (Napoli) 1994; 16: 97-102.
18. Schwartzman RJ, Gurusinghe C, Gracely E. Prevalence of complex regional pain syndrome in a cohort of multiple sclerosis patients. Pain Physician 2008; 11: 133-6.
19. Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology 1995; 45: 1294-6.
20. Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler 2005; 11: 398-402.
21. Kanchandani R, Howe JG. Lhermitte's sign in multiple sclerosis: a clinical survey and review of the literature. J Neurol Neurosurg Psychiatry 1982; 45: 308-12.
22. Lepore FE. The origin of pain in optic neuritis. Determinants of pain in 101 eyes with optic neuritis. Arch Neurol 1991; 48: 748-9.
23. Fazzone HE, Lefton DR, Kupersmith MJ. Optic neuritis: correlation of pain and magnetic resonance imaging. Ophthalmology 2003; 110: 1646-9.
24. Aguirregomozcorta M, Ramió-Torrentà L, Gich J, Quiles A, Genís D. Paroxysmal dystonia and pathological laughter as a first manifestation of multiple sclerosis. Mult Scler 2008; 14: 262-5.
25. Crayton H, Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology 2004; 63: 12-8.
26. Spissu A, Cannas A, Ferrigno P, Pelaghi AE, Spissu M. Anatomic correlates of painful tonic spasms in multiple sclerosis. Mov Disord 1999; 14: 331-5.
27. Osterman PO, Westerberg CE. Paroxysmal attacks in multiple sclerosis. Brain 1975; 98: 189-202.
28. Waubant E, Alizé P, Tourbah A, Agid Y. Paroxysmal dystonia (tonic spasm) in multiple sclerosis. Neurology 2001; 57: 2320-1.
29. Solaro C, Brichetto G, Amato MP, Cocco E, Colombo B, D'Aleo G, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004; 63: 919-21.
30. Warke K, Al-Smadi J, Baxter D, Walsh DM, Lowe-Strong AS. Efficacy of transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain in a multiple sclerosis population: a randomized, placebo-controlled clinical trial. Clin J Pain 2006; 22: 812-9.
31. Watkins SM, Espir M. Migraine and multiple sclerosis. J Neurol Neurosurg Psychiatry 1969; 32: 35-7.
32. Freedman MS, Gray TA. Vascular headache: a presenting symptom of multiple sclerosis. Can J Neurol Sci 1989; 16: 63-6.
33. Sandyk R, Awerbuch GI. The co-occurrence of multiple sclerosis and migraine headache: the serotoninergic link. Int J Neurosci 1994; 76: 249-57.
34. Gee JR, Chang J, Dublin AB, Vijayan N. The association of brainstem lesions with migraine-like headache: an imaging study of multiple sclerosis. Headache 2005; 45: 670-7.
35. Rolak LA, Brown S. Headaches and multiple sclerosis: a clinical study and review of the literature. J Neurol 1990; 237: 300-2.
36. Leandri M, Cruccu G, Gottlieb A. Cluster headache-like pain in multiple sclerosis. Cephalalgia 1999; 19: 732-4.
37. Pöllmann W, Erasmus LP, Feneberg W, Then-Bergh F, Straube A. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS. Neurology 2002; 59: 636-9.
38. Waxman SG. Acquired channelopathies in nerve injury and MS. Neurology 2001; 56: 1621-7.
39. Zhang J, Huang Y. The immune system: a new look at pain. Chin Med J 2006; 119: 930-8.
40. Gutrecht JA, Zamani AA, Salgado ED. Anatomic-radiologic basis of Lhermitte's sign in multiple sclerosis. Arch Neurol 1993; 50: 849-51.
41. Aicher SA, Silverman MB, Winkler CW, Bebo BF. Hyperalgesia in an animal model of multiple sclerosis. Pain 2004; 110: 560-70.
42. Watkins LR, Maier SF. The pain of being sick: implications of immune-to-brain communication for understanding pain. Ann Rev Psychol 2000; 51: 29-57.
43. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 2838-46.
44. Hansson E. Could chronic pain and spread of pain sensation be induced and maintained by glial activation? Acta Physiol 2006; 187: 321-7.
45. Love S, Gradidge T, Coakham HB. Trigeminal neuralgia due to multiple sclerosis: ultrastructural findings in trigeminal rhizotomy specimens. Neuropathol Appl Neurobiol 2001; 27: 238-44.
46. Morin C, Bushnell MC, Luskin MB, Craig AD. Disruption of thermal perception in a multiple sclerosis patient with central pain. Clin J Pain 2002; 18: 191-5.
47. Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999; 162: 162-8.
48. Bermejo PE, Velasco R. Nuevos fármacos antiepilépticos y dolor neuropático. De la medicina molecular a la clínica. Med Clin (Barc) 2007; 129: 542-50.
49. Watson CP. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain 2000; 16: 49-55.
50. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, openlabel, 2-year extension trial. Clin Ther 2007; 29: 2068-79.
51. Baker D, Jackson SJ, Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol 2007; 152: 649-54.
52. Pertwee RG. Cannabinoids and multiple sclerosis. Mol Neurobiol 2007; 36: 45-59.
53. Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006; 253: 1337-41.
54. Marco EM, Viveros M. Implicación funcional del sistema cannabinoide endógeno en la homeostasis emocional. Rev Neurol 2009; 48: 20-6.
55. Bermejo PE, Velasco R. Nuevos fármacos antiepilépticos en la profilaxis de la migraña. Med Clin (Barc) 2007; 128: 379-82.
56. Pascual-Gómez J. Papel de los neuromoduladores en el tratamiento preventivo de la migraña. Rev Neurol 2009; 49: 25-32.
57. Broggi G, Ferroli P, Franzini A, Nazzi V, Farina L, La Mantia L, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery 2004; 55: 830-8.
58. Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 2004; 97: 671-6.
59. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707-12.
60. Ben-Smail D, Peskine A, Roche N, Mailhan L, Thiébaut I, Bussel B. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler 2006; 12: 101-3.
61. Khan OA, Olek MJ. Clonidine in the treatment of spasticity in patients with multiple sclerosis. J Neurol 1995; 242: 712-3.
62. Haselkorn JK, Balsdon-Richer C, Fry-Welch D, Herndon RM, Johnson B, Little JW, et al. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 2005; 28: 167-99.